tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Body Weight D001835 333 associated lipids
Lung Neoplasms D008175 171 associated lipids
Adenocarcinoma D000230 166 associated lipids
Colonic Neoplasms D003110 161 associated lipids
Edema D004487 152 associated lipids
Carcinoma, Hepatocellular D006528 140 associated lipids
Hemolysis D006461 131 associated lipids
Cell Transformation, Neoplastic D002471 126 associated lipids
Inflammation D007249 119 associated lipids
Hypertension D006973 115 associated lipids
Glioma D005910 112 associated lipids
Weight Gain D015430 101 associated lipids
Insulin Resistance D007333 99 associated lipids
Hypercholesterolemia D006937 91 associated lipids
Diabetes Mellitus D003920 90 associated lipids
Brain Ischemia D002545 89 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Seizures D012640 87 associated lipids
Arteriosclerosis D001161 86 associated lipids
Atherosclerosis D050197 85 associated lipids
Diabetes Mellitus, Experimental D003921 85 associated lipids
Alzheimer Disease D000544 76 associated lipids
Stomach Ulcer D013276 75 associated lipids
Leukemia D007938 74 associated lipids
Hyperlipidemias D006949 73 associated lipids
Melanoma D008545 69 associated lipids
Colitis D003092 69 associated lipids
Liver Cirrhosis D008103 67 associated lipids
Cystic Fibrosis D003550 65 associated lipids
Reperfusion Injury D015427 65 associated lipids
Pain D010146 64 associated lipids
Dermatitis, Contact D003877 59 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Weight Loss D015431 56 associated lipids
Parkinson Disease D010300 53 associated lipids
Nerve Degeneration D009410 53 associated lipids
Leukemia, Myeloid D007951 52 associated lipids
Kidney Failure, Chronic D007676 51 associated lipids
Osteosarcoma D012516 50 associated lipids
Thrombosis D013927 49 associated lipids
Fatty Liver D005234 48 associated lipids
Precancerous Conditions D011230 48 associated lipids
Psoriasis D011565 47 associated lipids
Leukemia P388 D007941 43 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Hypersensitivity, Delayed D006968 43 associated lipids
Hyperalgesia D006930 42 associated lipids
Ischemic Attack, Transient D002546 42 associated lipids
Arthritis D001168 41 associated lipids
Hypotension D007022 41 associated lipids
Leukemia, Erythroblastic, Acute D004915 41 associated lipids
Neovascularization, Pathologic D009389 39 associated lipids
Lung Diseases D008171 37 associated lipids
Nervous System Diseases D009422 37 associated lipids
Heart Failure D006333 36 associated lipids
Glomerulonephritis D005921 35 associated lipids
Acne Vulgaris D000152 35 associated lipids
Infarction, Middle Cerebral Artery D020244 35 associated lipids
Fever D005334 35 associated lipids
Burns D002056 34 associated lipids
Spinal Cord Injuries D013119 34 associated lipids
Cataract D002386 34 associated lipids
Neurotoxicity Syndromes D020258 34 associated lipids
Acute Kidney Injury D058186 34 associated lipids
Ventricular Dysfunction, Left D018487 33 associated lipids
Memory Disorders D008569 33 associated lipids
Peripheral Nervous System Diseases D010523 33 associated lipids
Uremia D014511 33 associated lipids
Neurodegenerative Diseases D019636 32 associated lipids
Diarrhea D003967 32 associated lipids
Stroke D020521 32 associated lipids
Cardiomegaly D006332 31 associated lipids
Liver Diseases D008107 31 associated lipids
Dermatitis D003872 30 associated lipids
Drug Eruptions D003875 30 associated lipids
Proteinuria D011507 30 associated lipids
Catalepsy D002375 30 associated lipids
Kidney Diseases D007674 29 associated lipids
Obesity D009765 29 associated lipids
Ventricular Remodeling D020257 28 associated lipids
Brain Diseases D001927 27 associated lipids
Endotoxemia D019446 27 associated lipids
Autoimmune Diseases D001327 27 associated lipids
Encephalomyelitis, Autoimmune, Experimental D004681 26 associated lipids
Ascites D001201 25 associated lipids
Leukemia-Lymphoma, Adult T-Cell D015459 25 associated lipids
Pseudomonas Infections D011552 25 associated lipids
Cerebrovascular Disorders D002561 25 associated lipids
Colitis, Ulcerative D003093 24 associated lipids
Arthritis, Experimental D001169 24 associated lipids
Lymphoma, B-Cell D016393 24 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Genetic Predisposition to Disease D020022 24 associated lipids
Neoplasm Invasiveness D009361 23 associated lipids
Cholestasis D002779 23 associated lipids
Fibrosis D005355 23 associated lipids
Cystitis D003556 23 associated lipids
Leukemia, T-Cell D015458 23 associated lipids
Hypersensitivity D006967 22 associated lipids
Erythema D004890 22 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Hattori Y et al. Influence of cytochrome P450 3A5 polymorphisms on viral infection incidence in kidney transplant patients treated with tacrolimus. 2014 Transplant. Proc. pmid:24656015
Reggiani P et al. Conversion to rescue therapy with FK 506: data from eight liver transplant patients. 1994 Transplant. Proc. pmid:7527982
Lemmens HP et al. Outcome following orthotopic liver transplantation in HBsAg-positive patients using short- or long-term immunoprophylaxis. 1994 Transplant. Proc. pmid:7527983
Venkataramanan R et al. Pharmacokinetics of FK 506: preclinical and clinical studies. 1990 Transplant. Proc. pmid:1689899
Porayko MK et al. Nephrotoxicity of FK 506 and cyclosporine when used as primary immunosuppression in liver transplant recipients. 1993 Transplant. Proc. pmid:7679835
Shapiro R et al. Randomized trial of FK 506/prednisone vs FK 506/azathioprine/prednisone after renal transplantation: preliminary report. 1993 Transplant. Proc. pmid:7679836
Iwasaki K et al. Pharmacokinetic study of FK 506 in the rat. 1991 Transplant. Proc. pmid:1721268
Andersson J et al. FK 506 and cyclosporine inhibit antigen- or mitogen-induced monokine and lymphokine production in vitro. 1992 Transplant. Proc. pmid:1371621
Propper DJ et al. Effects of the immunosuppressive macrolides rapamycin and FK 506 in high responder rats presensitized to major histocompatibility complex antigens. 1993 Transplant. Proc. pmid:7679837
Kay JE et al. Uptake of FK 506 by lymphocytes and erythrocytes. 1991 Transplant. Proc. pmid:1721269
Matsuura T et al. Blockade of interleukin-2 production from cloned T cells by cyclosporine and FK 506 assessed by proliferation assays in vitro. 1992 Transplant. Proc. pmid:1371623
Van Buren D et al. Renal function in primary liver transplant recipients receiving neoral (cyclosporine) versus prograf (tacrolimus). 1998 Transplant. Proc. pmid:9636566
Nakai T et al. Immunosuppressive mechanism and immune tolerance of FK 506 in rat small bowel transplantation. 1996 Transplant. Proc. pmid:8623237
Jain A et al. Liver transplantation under tacrolimus in infants, children, adults, and seniors: long-term results, survival, and adverse events in 1000 consecutive patients. 1998 Transplant. Proc. pmid:9636567
Manu M et al. Impact of tacrolimus on hyperlipidemia after renal transplantation: a Japanese single center experience. 2000 Transplant. Proc. pmid:11119912
Weiler N et al. Tacrolimus effects and side effects after liver transplantation: is there a difference between immediate and extended release? 2013 Jul-Aug Transplant. Proc. pmid:23953543
Jin MB et al. Protective effect of FK 506 on hepatic energy metabolism in warm ischemic canine livers induced by total hepatic vascular exclusion. 1996 Transplant. Proc. pmid:8623243
Pascual J et al. Updated metaanalysis of steroid withdrawal in renal transplant patients on calcineurin inhibitor and mycophenolate mofetil. 2005 Transplant. Proc. pmid:16386525
Woodle ES et al. Role of protocol biopsies in the treatment of refractory renal allograft rejection with FK 506. 1996 Transplant. Proc. pmid:8623495
Rao P et al. Effect of FK 506 on FK-binding protein and transforming growth factor beta gene expression. 1991 Transplant. Proc. pmid:1721301
Peddi VR et al. Long-term kidney and pancreas function with tacrolimus immunosuppression following simultaneous kidney and pancreas transplantation. 1998 Transplant. Proc. pmid:9636626
Merli M et al. Conversion from twice-daily to once-daily tacrolimus administration in liver transplant patient. 2010 Transplant. Proc. pmid:20534292
Sawai T et al. A successful induction of tolerance by perioperative intrathymic injection in rat "high-responder" heart transplantation. 1999 Transplant. Proc. pmid:10578275
Uchida H et al. Chronopharmacology of tacrolimus in rats: toxicity and efficacy in a mouse-to-rat intestinal transplant model and its pharmacokinetic profile. 1999 Transplant. Proc. pmid:10578276
Oberholzer J et al. Immediate conversion from tacrolimus to cyclosporine in the treatment of posttransplantation diabetes mellitus. 2005 Transplant. Proc. pmid:15848603
Vincenti F et al. Prospective, multicenter, randomized trial to compare incidence of new-onset diabetes mellitus and glucose metabolism in patients receiving cyclosporine microemulsion versus tacrolimus after de novo kidney transplantation. 2005 Transplant. Proc. pmid:15848604
YaÄŸmurdur MC et al. Tacrolimus conversion in kidney transplant recipients: analysis of 107 patients. 2004 Jan-Feb Transplant. Proc. pmid:15013327
Akbas SH et al. Plasma homocysteine levels in renal transplant patients on tacrolimus therapy. 2004 Jan-Feb Transplant. Proc. pmid:15013332
Zhao J et al. Diabetes mellitus after living donor liver transplantation: data from mainland China. 2009 Transplant. Proc. pmid:19545722
DemirbaÅŸ A et al. Influence of tacrolimus plus mycophenolate mofetil regimens on acute rejection rate and diabetes mellitus development in renal transplant recipients. 2004 Jan-Feb Transplant. Proc. pmid:15013338
Fan Y et al. Tacrolimus versus cyclosporine for adult lung transplant recipients: a meta-analysis. 2009 Transplant. Proc. pmid:19545736
Mueller AR et al. Association between hepatitis and rejection: upregulation of cytokines and extracellular matrix parameters. 1997 Transplant. Proc. pmid:9365585
Spagnoletti G et al. Conversion from Prograf to Advagraf in stable kidney transplant recipients: better renal function after 3-year follow-up. 2014 Transplant. Proc. pmid:25242756
Costa JS et al. Polyomavirus Nephropathy: Ten-Year Experience. 2017 Transplant. Proc. pmid:28457399
Ito Y et al. Inhibition of epithelial replacement by nonspecific immunosuppressants accelerates rat orthotopic tracheal allograft rejection. 2002 Transplant. Proc. pmid:12176430
Kusne S et al. Infectious complications after small bowel transplantation in adults. 1994 Transplant. Proc. pmid:7518153
Masutani H et al. Suppression of the histologic changes of GVHD by FK 506 in rat small bowel transplantation. 1992 Transplant. Proc. pmid:1376519
Wennberg L et al. Efficacy of various immunosuppressive drugs in preventing pig-to-rat islet xenograft rejection. 1995 Transplant. Proc. pmid:7533391
Fung J et al. A randomized trial of primary liver transplantation under immunosuppression with FK 506 vs cyclosporine. 1991 Transplant. Proc. pmid:1721333
Land W Mycophenolate mofetil-based immunosuppressive therapy: induction, maintenance, and conversion protocols in renal transplantation. 1999 Transplant. Proc. pmid:10616558
Hasegawa A et al. Successful treatment of 115 pediatric renal transplant recipients with tacrolimus-based immunosuppressive therapy: a 7-year multicenter study in Japan. 2005 Transplant. Proc. pmid:15919460
Carmellini M et al. Excellent long-term results in de novo renal transplant recipients treated with proliferation signal inhibitors and reduced calcineurin inhibitors exposure. 2008 Jul-Aug Transplant. Proc. pmid:18675070
Cakir U et al. Role of Everolimus on Cardiac Functions in Kidney Transplant Recipients. 2017 Transplant. Proc. pmid:28340820
Tze WJ et al. FK 506: an effective immunosuppressant for islet xenotransplantation. 1992 Transplant. Proc. pmid:1281577
Kamei T et al. Established intraportal islet allograft is rejected despite the acceptance of donor-specific second cardiac allograft. 1992 Transplant. Proc. pmid:1281579
Ramirez CB et al. Early steroid withdrawal after liver transplantation. 1998 Transplant. Proc. pmid:9838406
Park CS et al. Tetrahydrocurcumin Ameliorates Tacrolimus-Induced Nephrotoxicity Via Inhibiting Apoptosis. 2018 Transplant. Proc. pmid:30401411
Jordan ML et al. FK 506 conversion of renal allografts failing cyclosporine immunosuppression. 1991 Transplant. Proc. pmid:1721365
Ko WJ et al. Clinical trial of FK506 in heart transplant patients in Taiwan: report of 7 cases with immunosuppression switch from cyclosporine to FK506. 1998 Transplant. Proc. pmid:9838474
Falkiewicz K et al. Renal function and tubular phosphate handling in long-term cyclosporine- and tacrolimus-based immunosuppression in kidney transplantation. 2006 Jan-Feb Transplant. Proc. pmid:16504680
Alessiani M et al. Infections in adult liver transplant patients under FK 506 immunosuppression. 1991 Transplant. Proc. pmid:1703345
Offner G et al. FK 506 in a 14-year-old renal allograft recipient with cyclosporine-related liver nephrotoxicity: 1-year follow-up. 1991 Transplant. Proc. pmid:1721366
Imai K et al. Histopathological study of canine pancreaticoduodenal allotransplantation with FK506, cyclosporine, and triple regimen immunosuppression. 1991 Transplant. Proc. pmid:1703347
Hernández D et al. Cardiovascular risk profile in nondiabetic renal transplant patients: cyclosporine versus tacrolimus. 2003 Transplant. Proc. pmid:12962773
Pascual J et al. A low incidence of new-onset insulin-dependent diabetes mellitus using tacrolimus in kidney recipients in Europe. 2003 Transplant. Proc. pmid:12962785
Bonatti H et al. Liver transplantation for acute liver failure in children under 1 year of age. 1997 Feb-Mar Transplant. Proc. pmid:9123068
Shapiro R Tacrolimus (FK-506) in kidney transplantation. 1997 Feb-Mar Transplant. Proc. pmid:9123077
Cicalese L et al. Effect of FK506 on the mucosal perfusion of the rat intestinal allograft. 1996 Transplant. Proc. pmid:8907959
Cho JH et al. Chronic rejection in pediatric liver transplantation. 1997 Feb-Mar Transplant. Proc. pmid:9123078
Reggiani P et al. Oral administration of FK 506 in a swine model of liver-small bowel allotransplantation. 1996 Transplant. Proc. pmid:8907965
Rashid I et al. Medium-term outcome using sirolimus-tacrolimus combination in adult renal transplant recipients. 2002 Transplant. Proc. pmid:12176520
Schwarz C et al. Tacrolimus, Mycophenolate Mofetil, and Low-Dose Steroids With or Without Interleukin-2 Receptor Antibody Induction Therapy: A Retrospective Cohort Analysis. 2015 Transplant. Proc. pmid:26518948
Yamamoto T et al. Efficacy of Eculizumab Therapy for Atypical Hemolytic Uremic Syndrome Recurrence and Antibody-Mediated Rejection Progress After Renal Transplantation With Preformed Donor-Specific Antibodies: Case Report. Transplant. Proc. pmid:28104125
Masaki Y et al. Cellular basis of acquired immunologic tolerance following total bowel transplantation in rats. I. Relation between donor lymphocyte chimerism and host-cell-mediated immunity. 1995 Transplant. Proc. pmid:7536971
McAlister VC et al. Oral delivery of liposomal tacrolimus: increased efficacy and reduced toxicity. 1999 Feb-Mar Transplant. Proc. pmid:10083495
Watanabe K et al. Prolongation effect of a small dose of FK506, cyclosporine, or azathioprine on renal allografts in dogs treated with fractionated lymphoid irradiation and donor bone marrow cell infusion. 1989 Transplant. Proc. pmid:2468213
Eidelman BH et al. Neurologic complications of FK 506. 1991 Transplant. Proc. pmid:1721398
Muirhead N et al. A comparison between cyclosporine and tacrolimus-based immunosuppression for renal allografts: renal function and blood pressure after 5 years. 2003 Transplant. Proc. pmid:14611965
Fang YH et al. AEB-071 versus tacrolimus monotherapy to prevent acute cardiac allograft rejection in the rat: a preliminary report. 2010 Transplant. Proc. pmid:20430219
Basadonna GP et al. Pancreas after kidney transplantation: HLA mismatch does not preclude success. 1997 Feb-Mar Transplant. Proc. pmid:9123470
Fellermann K et al. Tacrolimus: a new immunosuppressant for steroid refractory inflammatory bowel disease. 2001 Transplant. Proc. pmid:11377517
Suwelack B et al. Replacement of calcineurin inhibitors by mycophenolate mofetil: effect on hemoglobine levels. 2002 Transplant. Proc. pmid:12176585
Wilberg J et al. Oral tacrolimus bioavailability is increased after right split liver transplantation. 2007 Transplant. Proc. pmid:18089362
Adibelli Z et al. An unusual presentation of sirolimus associated cough in a renal transplant recipient. 2007 Transplant. Proc. pmid:18089408
Ji SM et al. Retrospective evaluation of the effect of mycophenolate mofetil dosage on survival of kidney grafts based on biopsy results. 2014 Transplant. Proc. pmid:25498056
Htun YY et al. CYP3A5*3 Genetic Polymorphism and Tacrolimus Concentration in Myanmar Renal Transplant Patients. 2018 Transplant. Proc. pmid:29731062
Salazar A et al. Sirolimus-tacrolimus combination for combined kidney-pancreas transplantation: effect on renal function. 2001 Feb-Mar Transplant. Proc. pmid:11267181
Park KM et al. Bone loss after orthotopic liver transplantation: FK 506 versus cyclosporine. 1996 Transplant. Proc. pmid:8658863
Ogasa N et al. Effect of FK 506 on growth of transplanted newborn rat intestine. 1991 Transplant. Proc. pmid:1721428
Kakefuda T et al. Detection of nitrosylhemoglobin in liver allograft in rats by using near-infrared spectroscopy. 1996 Transplant. Proc. pmid:8658885
Kino T et al. Effect of FK-506 on human mixed lymphocyte reaction in vitro. 1987 Transplant. Proc. pmid:2445071
Yoshimura R et al. Hepatocyte growth factor: a sensitive indicator for CsA-induced nephropathy. 1998 Transplant. Proc. pmid:9723373
Ueno T et al. Conversion to prolonged-release tacrolimus for pediatric living related donor liver transplant recipients. 2013 Transplant. Proc. pmid:23769087
Zajicek A et al. Thirteen years' experience in pediatric liver transplantation: differences between tacrolimus and cyclosporine. 2002 Transplant. Proc. pmid:12176653
Cintra-Cabrera M et al. Resistant Cytomegalovirus Infection After Renal Transplantation: Literature Review. 2018 Transplant. Proc. pmid:29579856
Heffron TG et al. Daclizumab induction in liver transplant recipients. 2001 Feb-Mar Transplant. Proc. pmid:11267408
Back JH et al. Antiproteinuric Effects of Green Tea Extract on Tacrolimus-Induced Nephrotoxicity in Mice. Transplant. Proc. pmid:26293093
Baskiran A et al. Pregnancy After Liver Transplantation: Risks and Outcomes. 2017 Transplant. Proc. pmid:28923640
Carrieri G et al. Effect of FK 506 in the prophylaxis of autoimmune glomerulonephritis in NZB/WF1 mice. 1991 Transplant. Proc. pmid:1721460
Nakai T et al. Immunologic changes in heterotopic and orthotopic small bowel transplantation in rats. 1999 Transplant. Proc. pmid:10500761
Krüger B et al. Different effects of cyclosporine or tacrolimus on hepatocyte acute phase proteins. 1998 Transplant. Proc. pmid:9636399
McAlister VC Liposomal tacrolimus: drug migration within blood compartments. 1998 Transplant. Proc. pmid:9636404
Bahra M et al. Significance of mycophenolate mofetil treatment in patients with HCV reinfection after liver transplantation: impact on clinical course and histologic damage. 2002 Transplant. Proc. pmid:12431663
Hesse CJ et al. Evaluation of the new EMIT enzyme immunoassay for the determination of whole-blood tacrolimus concentrations in kidney, heart, and liver transplant recipients. 2002 Transplant. Proc. pmid:12431679
Kacar S et al. Low-dose calcineurin inhibitor regimen combined with mammalian target of rapamycin inhibitors preserves kidney functions in renal transplant recipients without allograft nephropathy. 2010 Transplant. Proc. pmid:21094806
Shapiro R The development of tacrolimus in renal transplantation. 2001 Nov-Dec Transplant. Proc. pmid:11750356
Han SY et al. Effects of cyclosporine and tacrolimus on the oxidative stress in cultured mesangial cells. 2006 Transplant. Proc. pmid:16980053
Kumano K et al. FK 506-induced nephrotoxicity in rats. 1991 Transplant. Proc. pmid:1703696
Montero EF et al. Gangliosides on intestinal microcirculation and animal survival during reperfusion. 2004 Transplant. Proc. pmid:15194293
Morris-Stiff G et al. Conversion from cyclosporine to tacrolimus in renal allograft recipients with chronic graft nephropathy: preliminary report. 1998 Transplant. Proc. pmid:9636506